amylin glp 1 dual agonist Amylin: From Mode of Action to Future Clinical Potential in Diabetes and Obesity | Diabetes Therapy Amycretin — a novel obesity
Description
J Am Coll Cardiol 2024;84:1646-62.PubMed 98
for diabetes vs
From their identification as incretin hormones to development of long-acting analogue, GLP-1 agonists have revolutionized metabolic disease management
2022;27:e13211
This game changer is projected to grow significantly, potentially exceeding $126 billion by 2030
Can I switch from GLP-1 injections to pills
